Amgen, Inc. (AMGN) Misses Q4 EPS by 1c; Guides FY12 EPS

Amgen, Inc. (NASDAQ: AMGN) reported Q4 EPS of $1.21, $0.01 worse than the analyst estimate of $1.22. Revenue for the quarter came in at $3.97 billion versus the consensus estimate of $3.91 billion.

Amgen, Inc. sees FY2012 EPS of $5.90-$6.15, versus the consensus of $5.94.

For earnings history and earnings-related data on Amgen, Inc. (AMGN) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c